Abstract
High Resolution Assessment of Minimal Residual Disease (MRD) By Next-Generation Sequencing (NGS) and High-Sensitivity Flow Cytometry (hsFCM) in the Phase 3 GAIA (CLL13) Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have